Immune dysregulation increases the incidence of delayed‐type drug hypersensitivity reactions

TITLE : the genetics of drug hypersensitivity reactions

Hypersensitivity Reactions to oxaliplatin: incidence and management.

Oxaliplatin (Eloxatin) is a novel platinum compound that has activity in a wide variety of tumors. Several hypersensitivity reactions distinct from laryngopharyngeal dysesthesia have been described. We retrospectively analyzed 169 consecutive patients who received oxaliplatin for esophageal or colorectal cancer between 1/1/00 and 7/31/02 and reviewed any significant adverse reactions labeled as...

Evaluation of type I drug hypersensitivity reactions caused by chemotherapy in hospitalized children

Background and Objective: Type I drug hypersensitivity reactions causes immune responses that could endanger life. Therefore this study was designed with the aim of evaluation and register reactions that caused by chemotherapy in hospitalized children in Rasoul Akram Hospital in 2015. Methods: This is a descriptive, cross sectional study. All statistical calculation was performed using the v...

Diagnosis and management of drug hypersensitivity reactions.

The present article addresses the advances in the diagnosis and management of drug hypersensitivity reactions that were discussed in the 4th Drug Hypersensitivity Meeting held in Rome in April 2010. Such reactions can be classified as immediate or nonimmediate according to the time interval between the last drug administration and onset. Immediate reactions occur within 1 hour, and nonimmediate...

Drug hypersensitivity reactions: pathomechanism and clinical symptoms.

Small molecules, used as drugs, can induce immune reactions by binding covalently as haptens to a carrier protein, which is thereby modified and immunogenic. In addition, drugs bind to proteins via hydrogen bonds, electrostatic force, and van der Waals forces, and may directly interact with immune receptors such as T cell receptors or major histocompatibility complex molecules (pharmacologic in...